These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 32463489

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L.
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [Abstract] [Full Text] [Related]

  • 4. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green MD, Alva AS, Lao CD.
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ.
    J Immunother; 2017 Jan; 40(1):31-35. PubMed ID: 27846054
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
    Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL.
    J Immunother Cancer; 2017 Jan; 5():25. PubMed ID: 28331615
    [Abstract] [Full Text] [Related]

  • 14. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y, CheckMate 648 Trial Investigators.
    N Engl J Med; 2022 Feb 03; 386(5):449-462. PubMed ID: 35108470
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B, Rogala P, Czarnecka AM, Ługowska I, Teterycz P, Galus Ł, Rajczykowski M, Dawidowska A, Piejko K, Suwiński R, Mackiewicz J, Rutkowski P.
    Adv Med Sci; 2020 Sep 03; 65(2):316-323. PubMed ID: 32554313
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS.
    J Immunother Cancer; 2021 May 03; 9(5):. PubMed ID: 33963010
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.